Skip to main content

Table 1 Characteristics of randomized controlled trials included in the meta-analysis

From: Risk of second primary cancers in cancer patients treated with cisplatin: a systematic review and meta-analysis of randomized studies

Reference

Year of publication

Trial Phase

Cancer Type

Follow-up (month)

Total cisplatin dose(mg/m2)

Cisplatin Arm

Non-cisplatin Arm

Regimen

No. of Patients

Second Cancers (No.)

Leukemia (No.)

Regimen

No. of Patients

Second Cancers (No.)

Leukemia (No.)

Ajani et al..

2008

III

Anal

Median 30.1

Median 300

Fluorouracil, cisplatin and radiotherapy

320

1

 

Fluorouracil, mitomycin and radiotherapy

324

0

 

Basu et al

2016

II

Cervical

Median 29.2

Median 200

Cisplatin and radiotherapy

105

0

 

Interferon-alpha, retinoic acid and radiotherapy

104

1

 

Booton et al

2006

III

Lung

Median 17.4

Median 200

Mitomycin, ifosfamide and cisplatin or mitomycin, vinblastine and cisplatin

210

0

 

Docetaxel and carboplatin

212

1

 

Cohen et al

2014

III

Head and neck

Minimum 30

Median 150

Docetaxel, cisplatin and fluorouracil, followed by docetaxel, fluorouracil, and hydroxyurea plus radiotherapy

138

2

 

Docetaxel, fluorouracil, and hydroxyurea plus radiotherapy

135

1

 

Conroy et al

2014

II/III

Oesophageal

Median 25.3

Median 300

Fluorouracil, cisplatin and radiotherapy

133

7

 

Fluorouracil, leucovorin, oxaliplatin and radiotherapy

134

8

 

Cortelazzo et al

2012

III

Lymphoma

Median 27.7

Planned 300

Rituximab, cyclophosphamide, Ara-C, methotrexate, etoposide, cisplatin and autografting

121

0

 

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

127

0

 

du Bois et al

2003

III

Ovarian

Mean: 48.5 for cisplatin arm 49.9 for non-cisplatin arm

Median 441.6

Paclitaxel and cisplatin

386

9

0

Paclitaxel and carboplatin

397

9

0

Fleming et al

2004

III

Endometrial

Median 61 for alive patients

Planned 350

Doxorubicin and cisplatin

156

0

0

Doxorubicin and paclitaxel

157

1

1

Fountzilas et al

2004

III

Head and neck

Median 60

Median 270

Cisplatin and radiotherapy

45

1

 

Carboplatin and radiotherapy

38

1

 

Garden et al

2004

II

Head and neck

Median: 31.2–34.8

Median 100/140

Cisplatin, fluorouracil and radiotherapy vs cisplatin, paclitaxel and radiotherapy

155

6

 

Hydroxyurea, fluorouracil and radiotherapy

76

1

 

Geyer et al

2004

II

Brain

Median 79.2

Not reported

Vincristine, cisplatin, cyclophosphamide and etoposide

149

3

3

Vincristine, carboplatin, ifosfamide and etoposide

135

1

1

Harari et al

2014

II

Head and neck

Median 52.8

Median 180

Cisplatin, cetuximab and radiotherapy

97

4

 

Docetaxel, cetuximab and radiotherapy

106

12

 

Hiesiger et al

1995

Not reported

Brain

Median 26.5 for alive patients

Planned 720

Cisplatin

125

0

0

PCNU

145

1

1

Homma et al

2004

II

Head and neck

Median 63

Median 64

Cisplatin and radiotherapy

59

7

 

Carboplatin and radiotherapy

60

7

 

Intragumtornchai et al

2000

Not reported

Lymphoma

Median 36

Maximum 400

Etoposide, methylprednisolone, high-dosecytarabine, cisplatin, high-dose therapy and autologous peripheral blood progenitor cell transplantation

23

1

1

Cyclophosphamide,doxorubicin, vincristine and prednisolone

25

0

0

James et al

2013

III

Anus

Median 61.2

Planned 120/120/240

Cisplatin, fluorouracil and radiotherapy vs Mitomycin, fluorouracil, radiotherapy followed by cisplatin and fluorouracil vs Cisplatin, fluorouracil, radiotherapy followed by cisplatin and fluorouracil

694

17

 

Mitomycin, fluorouracil and radiotherapy

246

3

 

Jennings et al

2002

II

Glioma

Maximum 37

Median 300

Cisplatin, etoposide, cyclophosphamide and vincristine

31

0

0

Carboplatin, etoposide, and vincristine

32

1

1

Nicoletto et al

2007

Not reported

Ovarian

Median 178

Median 375

Cisplatin and cyclophosphamide

80

0

 

Adriamycin and cyclophosphamide

81

2

 

Nielsen et al

2000

III

Breast

Mean 17

Median 518

Epirubicin and cisplatin

74

3

3

Epirubicin

81

0

0

Olasz et al

2004

Not reported

Head and neck

Median 52

Median 120

Bleomycin, vincristine, methotrexate and cisplatin

19

1

 

Bleomycin, vincristine and methotrexate

19

1

 

Sirohi et al

2010

III

Breast

Median 112

Median 360

Epirubicin, cisplatin and 5-fluorouracil

172

3

 

5-fluorouracil, epirubicin and cyclophosphamide

177

11

 

Sutton et al

2000

III

Uterus

Maximum 24

Median 320

Ifosfamide and cisplatin

90

1

1

Ifosfamide

101

0

0

Taylor et al

1994

III

Ovarian

Median 108

Median 331.2

Cisplatin

64

0

 

Carboplatin

67

0

 

Tropé et al

1996

Not reported

Ovarian

Minimum 120

Planned 500

Cisplatin, doxorubicin and melphalan

143

4

4

Doxorubicin and melphalan

153

2

2

Tsimberidou et al

2002

Not reported

Lymphoma

Median 70.8

Planned 100

CHOD-Bleo, ESHAP, and NOPP

69

1

1

Fludarabine, mitoxantrone, and dexamethasone

1

73

1

Wada et al

1996

Not reported

Lung

Median 60

Mean 56.5

Cisplatin, vindesine, tegafur and uracil

109

3

 

Tegafur and uracil

103

2

 

Wadler et al

1996

III

Ovarian

Median 156 for alive patients

Median 580

Cyclophosphamid, hexamethylmelamine, doxorubicin, and cisplatin

126

0

 

Melphalan

118

1

 

Williams et al

1985

Not reported

Ovarian

Median 45

Planned 400

Cisplatin, doxorubicin, cyclophosphamide

40

1

1

Chlorambucil

44

0

0

  1. CHOD-Bleo cyclophosphamide, Doxorubicin, Vincristine, Bleomycin and Dexamethasone. ESHAP Etoposide, Methylprednisolone, Cytarabine and Cisplatin. NOPP Mitoxantrone, Vincristine, Procarbazine and Prednisone